Amorfix Provides Update on Alzheimer's Disease Diagnostic Program

Achieves Major Milestone and Plans to Seek Development Partner


TORONTO, Sept. 30, 2011 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced it has achieved 85 percent specificity and sensitivity with its EP-AD CSF Diagnostic Test.

Unlike tests that measure changes in the levels of non-aggregated Abeta 1-42, the Amorfix EP-AD CSF Diagnostic Test can detect the presence of the aggregated form which is strongly implicated in Alzheimer's disease (AD). When the scores from the Amorfix test were correlated with scores from the MMSE (Mini-Mental State Examination, a clinical test used to measure disease severity), the results demonstrated that aggregates were not only found in cerebrospinal fluid (CSF) from late-stage AD, but also in patients with early stage AD or mild cognitive impairment (MCI). In addition, the data suggest that the Amorfix test is superior for identification of patients with MCI when compared to the measurements of monomeric Abeta 1-42 alone.

"This accomplishment represents a significant step forward for our Alzheimer's disease diagnostic program", said Dr. Robert Gundel, President and Chief Executive Officer of Amorfix.  "We have developed a unique system for the detection of the aggregated Abeta peptide, a recognized biomarker for AD. As such, we see the utility of this assay as a means to dramatically improve the current state of AD diagnostics by improving clinicians' ability to properly identify patients with early stage disease.  In addition, our assay may be used as a way to significantly improve the accuracy and reduce the time and cost of conducting clinical trials for development of new treatments for AD.  We are now actively seeking a development partner to bring this important and valuable new asset to the market as quickly as possible."

About Alzheimer's Disease
More than 35 million people worldwide have Alzheimer's disease or other types of dementia. Alzheimer's disease is the most common type of dementia and accounts for an estimated 60-80 percent of cases. As the population around the world ages, the incidence of Alzheimer's disease (AD) is predicted to increase significantly. Barring a significant medical breakthrough, predictions are that cases of dementia will nearly double every 20 years, and by 2040 the number of cases around the world will quadruple to approximately 81 million people. A major stumbling block to the development of effective therapies is the absence of robust biomarkers that can be used for early detection and clinical monitoring during clinical trials. There is an obvious need for a diagnostic tool that can properly identify patients with AD in order for current therapeutics to be effective, and for enrollment into clinical trials designed to target these biomarker proteins.

About Amorfix

Amorfix Life Sciences Ltd. (TSX: AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD. For more information about Amorfix, visit

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Amorfix Life Sciences Ltd.

For further information:

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
Janet Clennett
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899

Profil de l'entreprise

Amorfix Life Sciences Ltd.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.